1. THÔNG BÁO VỀ VIỆC TUÂN THỦ QUY ĐỊNH PHÁP LUẬT KHI THAM GIA DIỄN ĐÀN

    Đề nghị toàn thể thành viên diễn đàn nghiêm túc tuân thủ Luật Chứng khoán, các quy định của Ủy ban Chứng khoán Nhà nước, đồng thời tuân thủ các quy định pháp luật liên quan đến an ninh mạng, giao dịch điện tử và trách nhiệm cá nhân khi đăng tải, chia sẻ thông tin trên môi trường mạng, bao gồm các quy định tại Nghị định 174/2026/NĐ-CP. xem thêm

Thực hư thuốc Remdesivir của Gilead, đem tin cũ ra xào lại?

Chủ đề trong 'Thị trường chứng khoán' bởi iStockVn, 17/04/2020.

Có 1768 người đang online, trong đó có 67 thành viên. 00:00 (UTC+07:00) Bangkok, Hanoi, Jakarta
  1. Có 1 người đang xem box này (Thành viên: 0, Khách: 1)
Chủ đề này đã có 3345 lượt đọc và 34 bài trả lời
  1. iStockVn

    iStockVn Thành viên gắn bó với f319.com

    Tham gia ngày:
    28/08/2010
    Đã được thích:
    5.308
    Khéo vụ fake news có 1 không hai
    China hồi tháng 2 cũng dùng thuốc này
    Nếu ngon nó đã la toáng lên :))

    công lực mạnh thì làm chai thuốc sâu công lực mạnh hơn nhìu
    Gilead Pours Cold Water On Report That Sent Market Soaring: "Anecdotal Reports With No Statistical Power"
    [​IMG]
    by Tyler Durden
    Thu, 04/16/2020 - 20:35
    TwitterFacebookRedditEmailPrint

    Statnews published a report by Adam Feuerstein, best known for doing the bidding of one or more hedge fund clients, according to which a "Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned."

    "Learned" from whom? A hedge fund or two who were long GILD and needed a fake news catalyst to get out? Because last time we checked, double blind, secret drug trials are, er... secret.

    The report went on: "patients using Gilead's remdesivir were "seeing rapid recoveries in fever and respiratory symptoms", which is odd considering the two previous incomplete/failed trials in China. According to the report, "almost all patients were discharged in under than a week, and only two patients died."

    the FT reported later - this time using facts not sources - "none of the patients on the Chicago trial had been on invasive ventilation", so is it possible that the drug killed them? Maybe Feuerstein can ask his hedge fund source.

    In any case, at the time the data hit Bloomberg around 4:21pm, it barely registered among the institutional audience, or even the algos, as most serious players were well aware of Feuerstein's "tactical" reputation.

    [​IMG]

    It wasn't until the news was reported by CNBC about 30 minutes later - and hit the retail investing audience - that GILD stock soared 16 and the entire market took off as if someone had suddenly discovered not only a cure but also a vaccine for coronavirus.

    Alas, neither happened, and as it has done on numerous occasions previously, about three hours after the news broke conveniently providing one or more hedge funds ample opportunity to offload their position in the thin after hours market, Gilead issued a statement which suggested that STAT was pumping the stock based on nothing more than "anecdotal reports" to wit:


    "We understand the urgent need for a Covid-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir. The totality of the data need to be analysed in order to draw any conclusions from the trial."

    "Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19. We expect the data from our Phase 3 study in patients with severe Covid-19 infection to be available at the end of this month, and additional data from other studies to become available in May."

    And so, one more attempt to ramp the market using fake news of an imminent drug has failed, with some observing that a Phase 1 drug trial is now the functional equivalent of a Phase 1 trade deal - both meaningless on their own, but with the power to send stocks surging when used tactically by unknown players.

    Experts had high hopes for remdesivir because it had shown it was effective in stopping the Ebola virus replicating. Ebola shares a similar mechanism of replication with Sars-CoV-2, the virus that causes the Covid-19 disease. However, there has been no definitive statistic evidence yet that that is the case.



    Investors should be cautious on the potential for Gilead’s drug Remdesivir, analysts say
    PUBLISHED FRI, APR 17 20207:08 AM EDTUPDATED AN HOUR AGO

    Julianna Tatelbaum




    KEY POINTS
    • The Barclays health-care team called the update “encouraging” but note that questions persist.
    • Jefferies equity analyst Michael J. Yee published in a research note that this Chicago report provides an “incremental positive.”
    • JPMorgan biotechnology equity analysts said that “this clinical trial experience appears to represent another encouraging, albeit largely anecdotal, data point for this high-profile drug candidate.”
    [​IMG]
    WATCH NOW
    VIDEO02:30
    Coronavirus patients reportedly responding to Gilead’s experimental treatment

    A new report from STAT News on Gilead’s experimental drug Remdesivir serves as an encouraging update on the drug’s potential to fight Covid-19, however analysts argue it’s largely anecdotal and should be interpreted with caution.

    Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.

    According to the report from an ongoing phase three trial at a University of Chicago hospital, patients showing severe Covid-19 symptoms who were given the drug saw rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than one week

  2. tantan799

    tantan799 Thành viên này đang bị tạm khóa Đang bị khóa Not Official

    Tham gia ngày:
    23/10/2017
    Đã được thích:
    130
    Không bắt đáy ôm 1 năm được rồi bác ạ, hợp đồng tương lai dầu nó cũng có đáo hạn như phái sinh. Nay giá tháng 5 đang 16 mà giá tháng 6 thì là 24, em cũng ko chơi forex bao giờ nên giờ mới biết :))
  3. chuquyenpn

    chuquyenpn Thành viên gắn bó với f319.com

    Tham gia ngày:
    07/12/2014
    Đã được thích:
    3.129
  4. iStockVn

    iStockVn Thành viên gắn bó với f319.com

    Tham gia ngày:
    28/08/2010
    Đã được thích:
    5.308
    trước nó khá sát nhau giữa các tháng nên cũng k để ý
    lần này nó vênh nhau quá, nhiều ng trade lâu năm cũng lần đầu thấy hiện tượng này và cũng k hiểu
    mai giá 24-25 thì cũng chả ngon lắm
    nói chung là chứng khoán đã hết sóng to
    ae lại bắt đầu phải tranh nhau đoạn đầu thừa đuôi thẹo rồiư

    bạn mình hô mình mua lúc giá đang 25 (hđ tháng 5), may mà không tham, k thì toi rồi
    Last edited: 20/04/2020
    tantan799 thích bài này.
  5. iStockVn

    iStockVn Thành viên gắn bó với f319.com

    Tham gia ngày:
    28/08/2010
    Đã được thích:
    5.308
    Mất hàng hay ôm bom bác?

Chia sẻ trang này